Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 336,772
  • Shares Outstanding, K 15,001
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,470 K
  • EBIT $ -69 M
  • EBITDA $ -68 M
  • 60-Month Beta 2.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.85

Options Overview Details

View History
  • Implied Volatility 224.52% ( +44.01%)
  • Historical Volatility 67.25%
  • IV Percentile 97%
  • IV Rank 29.26%
  • IV High 722.53% on 12/19/23
  • IV Low 18.58% on 01/05/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 218
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 2,796
  • Open Int (30-Day) 2,604

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.27
  • Number of Estimates 5
  • High Estimate -1.11
  • Low Estimate -1.36
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +15.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.24 +9.20%
on 11/19/24
26.05 -19.35%
on 12/03/24
+0.99 (+4.95%)
since 11/18/24
3-Month
14.42 +45.70%
on 10/10/24
26.05 -19.35%
on 12/03/24
-1.73 (-7.61%)
since 09/18/24
52-Week
4.40 +377.50%
on 12/19/23
31.01 -32.25%
on 04/01/24
+16.41 (+356.74%)
since 12/18/23

Most Recent Stories

More News
Insider Sale: Chief Operating Officer of $JSPR (JSPR) Sells 900 Shares

Jeetinder Singh Mahal, the Chief Operating Officer of $JSPR ($JSPR), sold 900 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

JSPR : 21.01 (-6.41%)
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab for Allergic Asthma

Jasper Therapeutics initiates Phase 1b/2a study of briquilimab for allergic asthma, targeting mast cell-driven diseases.Quiver AI SummaryJasper Therapeutics, Inc. has announced the dosing of the first...

JSPR : 21.01 (-6.41%)
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

JSPR : 21.01 (-6.41%)
Jasper Therapeutics to Participate at Upcoming Investor Conferences

JSPR : 21.01 (-6.41%)
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

JSPR : 21.01 (-6.41%)
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

JSPR : 21.01 (-6.41%)
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria

JSPR : 21.01 (-6.41%)
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

JSPR : 21.01 (-6.41%)
1 'Strong Buy' Small-Cap With 276% Upside Potential

As Jasper embarks on promising clinical trials and reports narrower losses, analysts remain bullish, setting ambitious price targets that could indicate substantial returns for investors.

IWM : 220.84 (-4.43%)
$SPX : 5,872.16 (-2.95%)
$IUXX : 21,209.31 (-3.60%)
JSPR : 21.01 (-6.41%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 90.69 (-2.27%)
AMGN : 258.78 (-2.70%)
BMY : 56.84 (-1.41%)
NVS : 96.83 (-2.29%)
BGNE : 175.87 (-1.78%)
JSPR : 21.01 (-6.41%)
VIGL : 1.6500 (-4.62%)
ALVR : 0.4500 (-1.53%)
RCUS : 15.17 (-5.66%)
FLACU : 9.50 (+2.48%)

Business Summary

Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 24.61
2nd Resistance Point 23.72
1st Resistance Point 22.37
Last Price 21.01
1st Support Level 20.13
2nd Support Level 19.24
3rd Support Level 17.89

See More

52-Week High 31.01
Last Price 21.01
Fibonacci 61.8% 20.84
Fibonacci 50% 17.70
Fibonacci 38.2% 14.57
52-Week Low 4.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar